Oppenheimer Lowers Keros Therapeutics (NASDAQ:KROS) Price Target to $63.00

Keros Therapeutics (NASDAQ:KROS) had its price target decreased by analysts at Oppenheimer from $102.00 to $63.00 in a report released on Monday, Marketbeat reports. The brokerage currently has an “outperform” rating on the stock. Oppenheimer’s price objective suggests a potential upside of 250.00% from the company’s current price.

A number of other equities analysts have also weighed in on KROS. Guggenheim lowered Keros Therapeutics from a “buy” rating to a “neutral” rating in a research note on Monday. Scotiabank lowered their price target on Keros Therapeutics from $77.00 to $44.00 and set a “sector outperform” rating for the company in a report on Friday, December 13th. Cantor Fitzgerald restated an “overweight” rating on shares of Keros Therapeutics in a research report on Friday, November 22nd. Jefferies Financial Group initiated coverage on shares of Keros Therapeutics in a report on Tuesday, November 5th. They issued a “buy” rating for the company. Finally, Bank of America reduced their price target on Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating on the stock in a research report on Thursday, September 12th. Four investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $81.33.

Keros Therapeutics Stock Down 7.3 %

NASDAQ:KROS opened at $18.00 on Monday. The firm has a market capitalization of $729.13 million, a P/E ratio of -3.45 and a beta of 1.20. Keros Therapeutics has a 12-month low of $15.67 and a 12-month high of $73.00. The stock’s fifty day simple moving average is $57.46 and its 200-day simple moving average is $52.30.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing the consensus estimate of ($1.28) by ($0.13). The company had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The company’s quarterly revenue was up 4750.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.33) earnings per share. As a group, equities research analysts expect that Keros Therapeutics will post -5.26 earnings per share for the current year.

Hedge Funds Weigh In On Keros Therapeutics

Large investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC purchased a new stake in shares of Keros Therapeutics in the second quarter valued at about $532,000. Assenagon Asset Management S.A. purchased a new position in shares of Keros Therapeutics in the 2nd quarter worth about $1,118,000. Bank of New York Mellon Corp grew its position in Keros Therapeutics by 18.8% during the second quarter. Bank of New York Mellon Corp now owns 118,388 shares of the company’s stock valued at $5,410,000 after buying an additional 18,755 shares during the period. Rhumbline Advisers increased its holdings in Keros Therapeutics by 20.6% during the second quarter. Rhumbline Advisers now owns 41,638 shares of the company’s stock worth $1,903,000 after buying an additional 7,111 shares during the last quarter. Finally, Arizona State Retirement System raised its position in Keros Therapeutics by 16.3% in the second quarter. Arizona State Retirement System now owns 8,077 shares of the company’s stock worth $369,000 after acquiring an additional 1,130 shares during the period. Institutional investors own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.